Cargando…
Optimizing effector functions of monoclonal antibodies via tailored N-glycan engineering using a dual landing pad CHO targeted integration platform
Monoclonal antibodies (mAbs) eliminate cancer cells via various effector mechanisms including antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC), which are influenced by the N-glycan structures on the Fc region of mAbs. Manipulating these glycan structur...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10511539/ https://www.ncbi.nlm.nih.gov/pubmed/37731040 http://dx.doi.org/10.1038/s41598-023-42925-1 |
_version_ | 1785108164052516864 |
---|---|
author | Nguyen, Ngan T. B. Leung, Hau Wan Pang, Kuin Tian Tay, Shi Jie Walsh, Ian Choo, Andre B. H. Yang, Yuansheng |
author_facet | Nguyen, Ngan T. B. Leung, Hau Wan Pang, Kuin Tian Tay, Shi Jie Walsh, Ian Choo, Andre B. H. Yang, Yuansheng |
author_sort | Nguyen, Ngan T. B. |
collection | PubMed |
description | Monoclonal antibodies (mAbs) eliminate cancer cells via various effector mechanisms including antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC), which are influenced by the N-glycan structures on the Fc region of mAbs. Manipulating these glycan structures on mAbs allows for optimization of therapeutic benefits associated with effector functions. Traditional approaches such as gene deletion or overexpression often lead to only all-or-nothing changes in gene expression and fail to modulate the expression of multiple genes at defined ratios and levels. In this work, we have developed a CHO cell engineering platform enabling modulation of multiple gene expression to tailor the N-glycan profiles of mAbs for enhanced effector functions. Our platform involves a CHO targeted integration platform with two independent landing pads, allowing expression of multiple genes at two pre-determined genomic sites. By combining with internal ribosome entry site (IRES)-based polycistronic vectors, we simultaneously modulated the expression of α-mannosidase II (MANII) and chimeric β-1,4-N-acetylglucosaminyl-transferase III (cGNTIII) genes in CHO cells. This strategy enabled the production of mAbs carrying N-glycans with various levels of bisecting and non-fucosylated structures. Importantly, these engineered mAbs exhibited different degrees of effector cell activation and CDC, facilitating the identification of mAbs with optimal effector functions. This platform was demonstrated as a powerful tool for producing antibody therapeutics with tailored effector functions via precise engineering of N-glycan profiles. It holds promise for advancing the field of metabolic engineering in mammalian cells. |
format | Online Article Text |
id | pubmed-10511539 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-105115392023-09-22 Optimizing effector functions of monoclonal antibodies via tailored N-glycan engineering using a dual landing pad CHO targeted integration platform Nguyen, Ngan T. B. Leung, Hau Wan Pang, Kuin Tian Tay, Shi Jie Walsh, Ian Choo, Andre B. H. Yang, Yuansheng Sci Rep Article Monoclonal antibodies (mAbs) eliminate cancer cells via various effector mechanisms including antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC), which are influenced by the N-glycan structures on the Fc region of mAbs. Manipulating these glycan structures on mAbs allows for optimization of therapeutic benefits associated with effector functions. Traditional approaches such as gene deletion or overexpression often lead to only all-or-nothing changes in gene expression and fail to modulate the expression of multiple genes at defined ratios and levels. In this work, we have developed a CHO cell engineering platform enabling modulation of multiple gene expression to tailor the N-glycan profiles of mAbs for enhanced effector functions. Our platform involves a CHO targeted integration platform with two independent landing pads, allowing expression of multiple genes at two pre-determined genomic sites. By combining with internal ribosome entry site (IRES)-based polycistronic vectors, we simultaneously modulated the expression of α-mannosidase II (MANII) and chimeric β-1,4-N-acetylglucosaminyl-transferase III (cGNTIII) genes in CHO cells. This strategy enabled the production of mAbs carrying N-glycans with various levels of bisecting and non-fucosylated structures. Importantly, these engineered mAbs exhibited different degrees of effector cell activation and CDC, facilitating the identification of mAbs with optimal effector functions. This platform was demonstrated as a powerful tool for producing antibody therapeutics with tailored effector functions via precise engineering of N-glycan profiles. It holds promise for advancing the field of metabolic engineering in mammalian cells. Nature Publishing Group UK 2023-09-20 /pmc/articles/PMC10511539/ /pubmed/37731040 http://dx.doi.org/10.1038/s41598-023-42925-1 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Article Nguyen, Ngan T. B. Leung, Hau Wan Pang, Kuin Tian Tay, Shi Jie Walsh, Ian Choo, Andre B. H. Yang, Yuansheng Optimizing effector functions of monoclonal antibodies via tailored N-glycan engineering using a dual landing pad CHO targeted integration platform |
title | Optimizing effector functions of monoclonal antibodies via tailored N-glycan engineering using a dual landing pad CHO targeted integration platform |
title_full | Optimizing effector functions of monoclonal antibodies via tailored N-glycan engineering using a dual landing pad CHO targeted integration platform |
title_fullStr | Optimizing effector functions of monoclonal antibodies via tailored N-glycan engineering using a dual landing pad CHO targeted integration platform |
title_full_unstemmed | Optimizing effector functions of monoclonal antibodies via tailored N-glycan engineering using a dual landing pad CHO targeted integration platform |
title_short | Optimizing effector functions of monoclonal antibodies via tailored N-glycan engineering using a dual landing pad CHO targeted integration platform |
title_sort | optimizing effector functions of monoclonal antibodies via tailored n-glycan engineering using a dual landing pad cho targeted integration platform |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10511539/ https://www.ncbi.nlm.nih.gov/pubmed/37731040 http://dx.doi.org/10.1038/s41598-023-42925-1 |
work_keys_str_mv | AT nguyenngantb optimizingeffectorfunctionsofmonoclonalantibodiesviatailorednglycanengineeringusingaduallandingpadchotargetedintegrationplatform AT leunghauwan optimizingeffectorfunctionsofmonoclonalantibodiesviatailorednglycanengineeringusingaduallandingpadchotargetedintegrationplatform AT pangkuintian optimizingeffectorfunctionsofmonoclonalantibodiesviatailorednglycanengineeringusingaduallandingpadchotargetedintegrationplatform AT tayshijie optimizingeffectorfunctionsofmonoclonalantibodiesviatailorednglycanengineeringusingaduallandingpadchotargetedintegrationplatform AT walshian optimizingeffectorfunctionsofmonoclonalantibodiesviatailorednglycanengineeringusingaduallandingpadchotargetedintegrationplatform AT chooandrebh optimizingeffectorfunctionsofmonoclonalantibodiesviatailorednglycanengineeringusingaduallandingpadchotargetedintegrationplatform AT yangyuansheng optimizingeffectorfunctionsofmonoclonalantibodiesviatailorednglycanengineeringusingaduallandingpadchotargetedintegrationplatform |